Aspirin-exacerbated respiratory disease (AERD) is characterized by persistent chronic inflammation of the upper and lower airways leading to chronic rhinosinusitis, nasal polyposis, and asthma. When individuals with AERD ingest aspirin or other inhibitors of cyclooxygenase 1 they develop acute worsening of their rhinosinusitis accompanied by acute bronchoconstriction that may be life-threatening. AERD affects ~10% of adults with asthma, yet the fundamental underlying mechanisms remain unknown. Biochemically, AERD is characterized by abnormalities in eicosanoid generation and function. There is increased generation of cysteinyl leukotrienes at baseline and further release in response to inhibition of cyclooxygenase 1. The bronchoconstrictor response to leukotriene E4 is increased. Respiratory tissues of individuals with AERD show increased expression of the type 1 cysteinyl leukotriene receptor and diminished expression of cyclooxygenase 2 and the type 2 receptor for prostaglandin E2. Our preliminary data indicate that respiratory tissue from individuals with AERD avidly metabolize arachidonic acid to at least three major metabolites, one of which we identified at 15-HETE;the other 2 metabolites have not been identified. This strikingly abnormal eicosanoid profile indicates the involvement of previously unrecognized arachidonate metabolites in the pathobiology of AERD. The abnormalities in eicosanoid generation and responsiveness in AERD lack a coherent explanation, and state-of-the-art technology has not been applied to their investigation. We propose to use two state-of-the-art techniques to address the fundamental mechanisms of AERD. We will use sequential liquid chromatography/tandem mass spectrometry to provide a comprehensive analysis of the lipid mediators generated by nasal polyp tissue from individuals with AERD compared to aspirin-tolerant asthmatics with chronic rhinosinusitis. We will combine this with genome-wide analysis of the transcriptome of nasal polyps from the same individuals. This combined approach will allow us to evaluate the gene expression signature in AERD for enrichment of defined functional gene networks that underlie the inflammatory process and the abnormalities in lipid mediator generation. Success will lead to a significant break-through in our understanding of AERD, will spur the development of new treatments for AERD, and will allow the development of novel diagnostic tools that do rely on potentially dangerous in vivo provocation tests with aspirin.

Public Health Relevance

Asthma is a common disease that affects about 15% of the population of the United States, and about one in every ten adults with asthma develops life-threatening attacks of asthma when they ingest aspirin or similar analgesics. These individuals suffer from debilitating sinus disease and severe asthma.
The aim of this proposal is to use state-of-the art analyses of the lipid mediators that are generated and the genes that are expressed in the airways of individuals with aspirin-exacerbated respiratory disease in order to provide key new insights into the mechanisms of this disease, its diagnosis, and its treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI082369-01A1
Application #
7739258
Study Section
Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section (HAI)
Program Officer
Togias, Alkis
Project Start
2009-08-01
Project End
2011-07-31
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
1
Fiscal Year
2009
Total Cost
$266,500
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Liu, Tao; Barrett, Nora A; Kanaoka, Yoshihide et al. (2018) Type 2 Cysteinyl Leukotriene Receptors Drive IL-33-Dependent Type 2 Immunopathology and Aspirin Sensitivity. J Immunol 200:915-927
Samuchiwal, Sachin K; Balestrieri, Barbara; Raff, Hannah et al. (2017) Endogenous prostaglandin E2 amplifies IL-33 production by macrophages through an E prostanoid (EP)2/EP4-cAMP-EPAC-dependent pathway. J Biol Chem 292:8195-8206
Liu, Tao; Kanaoka, Yoshihide; Barrett, Nora A et al. (2015) Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway. J Immunol 195:3537-45
Liu, Tao; Garofalo, Denise; Feng, Chunli et al. (2015) Platelet-driven leukotriene C4-mediated airway inflammation in mice is aspirin-sensitive and depends on T prostanoid receptors. J Immunol 194:5061-8
Laidlaw, Tanya M; Cutler, Anya J; Kidder, Molly S et al. (2014) Prostaglandin E2 resistance in granulocytes from patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 133:1692-701.e3
Cummings, Hannah E; Liu, Tao; Feng, Chunli et al. (2013) Cutting edge: Leukotriene C4 activates mouse platelets in plasma exclusively through the type 2 cysteinyl leukotriene receptor. J Immunol 191:5807-10
Liu, Tao; Laidlaw, Tanya M; Katz, Howard R et al. (2013) Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. Proc Natl Acad Sci U S A 110:16987-92
Laidlaw, Tanya M; Kidder, Molly S; Bhattacharyya, Neil et al. (2012) Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood 119:3790-8
Giannattasio, Giorgio; Ohta, Shin; Boyce, Joshua R et al. (2011) The purinergic G protein-coupled receptor 6 inhibits effector T cell activation in allergic pulmonary inflammation. J Immunol 187:1486-95
Laidlaw, Tanya M; Steinke, John W; Tinana, Adrienne M et al. (2011) Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcýýRI. J Allergy Clin Immunol 127:815-22.e1-5